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Congenital Cytomegalovirus:  A European expert consensus statement on diagnosis and 
management. 
Introduction 
Congenital CMV (cCMV) is the most common congenital infection in the developed world.  
Reported prevalence varies between cohorts but is approximately 7 per 1000 births.1  About 
half of CMV-infected babies with clinically detectable disease at birth are destined to have 
significant impairments in their development and cCMV infection is implicated in around 
25% of all children with sensorineural hearing loss (SNHL). 1;2  Meta-analysis shows that 
although long-term sequelae, especially SNHL, are more common in those with clinically 
detectable disease at birth they are also found in 13% of those without clinical features 
attributable to CMV on initial examination.1 
Despite the significant long-term impact of cCMV infection there is limited evidence on 
which to base many treatment decisions in clinical practice.  In an era of enhanced antenatal 
screening fetuses and newborns are increasingly tested for CMV following abnormalities 
detected during routine ultrasonography or maternal serology.  Furthermore, otherwise 
“asymptomatic”, congenitally CMV-infected, newborns are being identified following 
detection of SNHL through newborn hearing screening programs (NHSP).   Babies with cCMV 
now presenting to pediatricians therefore differ from those primarily included in clinical 
trials of treatment reported in the literature. 
A symposium was convened during the 2015 conference of the European Society of 
Paediatric Infectious Diseases (ESPID) to discuss the current management of cCMV.  In 
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attendance were clinicians from throughout Europe, many of whom are involved in policy 
for cCMV for their region/country. 
This paper summarizes the discussions at this meeting alongside the evidence informing 
them.  A balanced perspective of the controversies in this area is presented and areas of 
consensus highlighted.  Finally where evidence is lacking suggestions are made for future 
research efforts to address areas of unmet medical need.   
The authors acknowledge the coexisting need for studies on the management of babies with 
symptoms consistent with cCMV, but in whom this diagnosis cannot be firmly established, 
and of those with symptomatic postnatal CMV infection; this paper does not, however, 
address these groups.    
The internationally accepted GRADE system for evaluating evidence has been used to 
illustrate points where relevant (Table 1).3  
 
Definitions of Symptomatic disease 
Classically cCMV infection is categorized as “symptomatic” or “asymptomatic” at birth.  
Differing definitions and opinions on what constitutes “symptomatic” CMV infection, 
however, makes interpreting the literature challenging.  Indeed, some of the largest cohort 
studies include babies with SNHL at birth in the group described as being “asymptomatic” 
since no “clinically apparent disease” was detectable during newborn examination.4  In 
modern healthcare systems, whereby cCMV is increasingly detected through screening for 
other conditions, alongside increased accessibility of investigations, such as MRI, the 
traditional dichotomy between clinically “apparent” and “inapparent” disease is becoming 
less meaningful.  Table 2 summarizes the accepted clinical features of cCMV disease with 
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those symptoms detectable on newborn examination listed separately to those detectable 
only if specific investigations are conducted, for example, when cCMV is already suspected.5-
8  
Full consensus within this expert group was that:- 
1) For the purposes of research and publication newborns identified as having cCMV 
disease following abnormal clinical examination at birth (such as microcephaly, small 
for gestational age (SGA), widespread petechiae, hepatosplenomegaly) should be 
differentiated from those babies identified through screening or investigation for 
other disorders e.g. those tested for CMV following known/likely maternal infection 
or abnormal newborn hearing screening. This differentiation would allow for more 
accurate assessment of the prognostic value of individual manifestations of 
“symptomatic” disease on longer-term outcomes as already shown in other 
publications.9  
2) “Symptomatic” cCMV should be considered as ‘severe’, ‘moderate’ or ‘mild’ disease.  
a. ‘Mild’ disease includes those with isolated (one, or two at most), otherwise 
clinically insignificant or transient findings such as, petechiae, mild 
hepatomegaly or splenomegaly or biochemical/hematological abnormalities 
(such as thrombocytopenia, anemia, leukopenia, borderline raised liver 
enzyme abnormalities or conjugated hyperbilirubinemia) or SGA (defined as 
weight for gestational age < -2 standard deviations (SD)) without 
microcephaly.  
b. ‘Severe’ disease includes those with CNS involvement (abnormal neurological 
or ophthalmological examination, microcephaly and/or neuroimaging 
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consistent with cCMV disease (such as calcifications, moderate to severe 
ventriculomegaly, cysts, white matter changes, cerebral or cerebellar 
hypoplasia, hippocampal dysplasia, neuronal migration abnormalities))10 
and/or with life-threatening disease. 
The majority agreed that:- 
2b.  ‘Severe’ disease also includes babies with evidence of severe single organ 
disease (including those with clinically significant liver enzyme abnormalities 
(liver ‘failure’) and marked hepatosplenomegaly) and/or those with 
significant multi-organ involvement.  Babies with transient or otherwise 
clinically insignificant abnormalities (i.e. the babies are not ‘sick’) that resolve 
spontaneously over a few weeks are not included in this group even if these 
abnormalities are multiple.   
2c.  A further group exists that may be considered to have ‘moderate’ disease.  
This group is heterogeneous and includes, for example, those with persistent 
(e.g. more than 2 weeks duration) abnormalities of hematological/biochemical 
indices and/or more than 2 ‘mild’ disease manifestations (as listed above).  
Due to lack of evidence full consensus could not be reached on how to 
approach this group and treatment decisions are currently made on a case by 
case basis.  Development of a validated clinical scoring system for disease 
severity at presentation and risk of sequelae would be beneficial for both 
counselling parents and informing treatment decisions. 
3) Defining CNS involvement 
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a. It remains uncertain whether some, non-specific findings detected on cranial 
ultrasound (CrUSS) and MRI (particularly isolated lenticulostriatal 
vasculopathy (LSV)) constitute clinically significant CNS disease.  LSV has been 
detected in 0.4%-5.8% of all neonates undergoing an ultrasound and only 5% 
has been associated with cCMV.11;12 Some have suggested isolated LSV as a 
marker of risk for SNHL.11 Others have found only more extensive 
neuroimaging abnormalities to be of prognostic value.13;14 The majority at 
this meeting would not consider LSV in isolation to be a notable CNS 
manifestation of disease.  It is suggested that neuro-radiological 
abnormalities not known to be clearly associated with CMV disease and 
adverse outcomes are discussed with a suitably experienced neuro-
radiologist, particularly if the results of these discussions might influence 
treatment decisions.     
b. The exact pathophysiology of SNHL is not clear but is likely secondary to 
infection and degradation of sensory structures within the inner ear 15;16. It is 
therefore debated whether isolated SNHL should truly be considered a CNS-
manifestation of infection and, as a consequence, whether such children 
should be considered comparable to those with CNS disease included in 
published clinical trials.  No studies have addressed this specific population, 
but a non-randomized cohort study observing the effects of valganciclovir in 
isolated SNHL is in progress (clinicaltrials.gov NCT02005822).  The majority of 
experts at this meeting would categorize babies with isolated, confirmed, 
SNHL in the ‘severe’/CNS group since bilateral SNHL is not only associated 
with likely long-term impairments but was also included in the criteria for 
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recruitment in the only randomized controlled trials (RCTs) in cCMV.  
However, consensus was not reached because the spectrum of hearing loss is 
wide and treatment of isolated SNHL has not been evaluated in any RCTs. 
When should testing for congenital CMV be considered? 
Indications for testing for cCMV are based on the presence of one or more of the most 
frequently observed clinical features (Table 3).17  Unfortunately predictive values for each of 
these features are not available. 
Full consensus within this expert group was that testing for cCMV should be performed in:- 
1) Fetuses with ultrasound/MRI imaging consistent with cCMV disease (by 
appropriately timed antenatal testing of amniotic fluid). 18(Quality C, Level 1) 
2) Newborns where there is a maternal history of suspected primary CMV infection 
during pregnancy.  If antenatal testing of amniotic fluid has been conducted it is 
suggested that cCMV infection should still be confirmed at birth since both false 
positive and negative results have been reported.18 (Quality C, Level 1)   
3) Newborns with signs/symptoms consistent with cCMV disease (see Table 2) 
(including those with findings consistent with cCMV on antenatal imaging).  
(Quality B, Strength 1)  
4) Children with confirmed SNHL.16  Systems need to be established to ensure 
testing for cCMV occurs, where possible, in the first 21 days of life since dried 
blood spot (DBS) are not always readily available for testing (see below).  (Quality 
B, Strength 1) 
The majority agreed that:- 
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5) Newborns that are small for gestational age (SGA) should not routinely be tested.   
Studies in SGA newborns have shown the prevalence of cCMV to be 0-5.2%.19-22  
However, the majority of studies report a prevalence of 1.4-1.8%, which is not 
significantly higher than the prevalence of cCMV in the general population.  
Therefore evidence is insufficient to justify screening all newborns with isolated 
SGA for cCMV.  None of these studies distinguish between asymmetrical (with 
normal head circumference) and symmetrical SGA but, when head circumference 
was mentioned, most SGA babies with cCMV had microcephaly (head 
circumference < -2 SD).21;22  Because of this, and the poor prognostic outcome of 
children with cCMV and microcephaly, many present at this meeting test those 
babies with symmetrical SGA but not those with preserved head 
growth.14(Quality C, Strength 2)  
6) Prematurity.  
Evidence that premature babies have a higher incidence of cCMV is limited.20;23  
Testing extremely premature babies (<28 weeks gestational age) at birth does, 
however, assist in differentiating between congenital and postnatal infection.  
This may be very helpful in guiding the management of these babies that are 
particularly vulnerable to symptomatic postnatal infection.  However, consensus 
was not reached regarding practice in this area with cost being a factor amongst 
other considerations.24 (Quality C, Strength 2)  
7) Testing of babies born to mothers who are known to be CMV seropositive at the 
establishment of pregnancy.   
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Although maternal non-primary CMV infection is known to be important when 
considering the overall burden of cCMV disease testing all babies born to these 
women, particularly in populations with high maternal seroprevalence, is 
tantamount to universal neonatal screening.25;26  Identifying women with non-
primary CMV who are at highest risk of transmitting infection to their fetus 
remains elusive.  It was agreed that individual case discussion and local policy 
should therefore dictate practice in this area.  Further research is clearly needed.   
 
Laboratory diagnosis of congenital CMV infection 
Testing for cCMV using CMV-PCR in urine is highly reliable; sensitivity is 100% and specificity 
99%.27 One negative urine specimen in a neonate is therefore sufficient to exclude infection 
and repeat sampling is not necessary.  After 21 days a urine positive for CMV could be due 
to CMV acquired postnatally from, for example, passage through the birth canal or through 
breast milk.  As CMV PCR techniques are becoming more sensitive earlier testing, before the 
age of 14 days, is recommended. 27 
CMV PCR testing of saliva is an alternative and is easy to perform.  Samples should be taken 
immediately before feeding in breastfed newborns, and confirmed with urine, as false 
positive results have been reported.28-31    
PCR assay of neonatal DBS can be performed retrospectively in an attempt to diagnose 
cCMV after the first 21 days of life. Sensitivity is around 84% in meta-analysis but is highly 
variable depending on the laboratory techniques used and the population being tested; a 
negative DBS PCR cannot therefore be used to definitively exclude a diagnosis of cCMV.32   
14 
 
Full consensus within this expert group was that:-  
1) Testing for cCMV should be performed using a single CMV PCR of urine obtained 
within 21 days of birth but ideally within 14 days of birth (Quality B, Strength 1).  
2) Saliva PCR testing can be an alternative but a positive result should be confirmed 
using urine (Quality B, Strength 1).  
3) After the age of 21 days CMV DNA PCR of stored DBS can be used to diagnose 
cCMV retrospectively; sensitivity is relatively low and a negative test cannot be used to 
definitively exclude a diagnosis of cCMV (Quality B, Strength 1). 
Recommended investigations after confirming a diagnosis of congenital CMV infection 
After a virological diagnosis of cCMV infection has been made, additional investigations are 
necessary to evaluate the extent of disease and to assist with discussions regarding 
prognosis and treatment.  
Full consensus within this expert group was that:-  
1) The investigations below are conducted in any baby in whom a diagnosis of cCMV is 
confirmed looking specifically for the manifestations of disease (Table 2): 
 Complete blood count, liver enzymes, (conjugated) bilirubin   
 Renal function (before initiating therapy)  
 Cranial ultrasound (CrUSS). (Quality A, Strength 1) 
 Audiological testing (brainstem evoked response; some screening tests such as 
otoacoustic emissions are not sufficient to detect central auditory hearing loss in 
cCMV). (Quality A, Strength 1) 
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 Ophthalmic assessment. (Quality A, Strength 1) 
2) If additional imaging to CrUSS is felt to be indicated then MRI is the preferred 
neuroimaging modality.  MRI can be successfully performed in neonates without the 
need for sedation and is therefore both highly sensitive and free of the risks of 
radiological exposure which accompany computed tomography (CT).  (Quality C, 
Strength 1)  
3) MRI should be performed in babies with clinically detectable neurological findings or 
CrUSS abnormalities. 
The majority agreed that:- 
4) Cranial MRI should be performed in any babies with cCMV and evidence of CMV 
disease (see table 2). (Quality C, Strength 1). 
5) CMV PCR quantitation should be performed in blood at baseline. 
Several studies have shown the absence of CMV viremia to be associated with better 
long-term outcomes and this may be reassuring when evaluating babies without any 
other manifestations of cCMV disease.33-35  Blood CMV PCR should not, however, be 
used to rule out cCMV infection since paradoxically the absence of CMV in blood has 
been described even in babies with severe cCMV disease.33;36 (Quality C, Strength 2) 
6) Examination of cerebrospinal fluid:  
No current evidence supports examination of cerebrospinal fluid (CSF) as part of 
routine diagnostic work up.  Studies have shown detectable CMV DNA in CSF and 
elevated biomarkers such as beta2-microglobulin suggest a poor prognosis.13;37  
However, others have shown no additional prognostic value from CSF specimens 
obtained in the clinical setting.37  Despite this lack of evidence there was a majority 
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view that, although a possible area of interest for future research, lumbar puncture 
should not be performed routinely in babies with cCMV infection (Quality C, Strength 
1). 
Only a minority agreed that:- 
7) Cranial MRI should be performed in all CMV-infected babies.   
Although there is no conclusive evidence that performing MRI gives additional 
prognostic information to CrUSS in those without evidence of CMV disease at birth 
some argued that it is desirable to conduct MRI in all cCMV infected babies since 
additional pathology can be identified as compared to CrUSS.38-40  (Quality D, 
Strength 2) 
Treatment 
No antiviral drugs are currently licensed for the treatment of cCMV.  Although many case 
reports and cohort studies have reported on treatment for cCMV there are results from only 
2 randomized controlled trials (RCTs).7;41-44  The first of these studies evaluated 6 weeks’ 
intravenous ganciclovir treatment in neonates (< 1 month of age), gestational age ≥32 
weeks, and clinically apparent disease in the newborn period with evidence of CNS disease 
(including microcephaly, intracranial calcification, abnormal CSF indices for age, hearing 
deficit and chorioretinitis).7  Improved hearing and neurodevelopmental outcomes were 
shown but there was significant loss to follow-up.7;44  A more recent trial compared 6 weeks 
to 6 months treatment with oral valganciclovir and included babies with any evidence of 
symptomatic (including non-CNS) cCMV disease.41  Few babies enrolled, however, had 
isolated, mild clinical features and none in the 6 month treatment group had isolated SNHL 
(D Kimberlin 2015, personal email correspondence, 28 April).  A modest benefit on both 2 
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year hearing and neurodevelopmental outcomes was shown with the 6 month treatment 
course.  The longer treatment course improved likelihood of better hearing outcomes most 
notably in those with pre-existing CNS involvement.  Longer duration of therapy was only 
statistically significant, however, for ‘total ear’ hearing as opposed to ‘best ear’ hearing 
(which is of greater functional significance) and only once adjusted for baseline CNS 
involvement.  Given the natural resolution of some features of cCMV disease in published 
cohorts, alongside the delayed onset of hearing loss and fluctuations in SNHL reported in 
cCMV, it is even more challenging to draw any conclusions regarding treatment effect from 
uncontrolled studies.7;16;45   
Clinical trials to date do not, therefore, provide good evidence on which to base treatment 
decisions for many of the infants presenting to clinicians in everyday clinical practice.   
Table 4 provides guidance on which infants should be offered treatment following a risk 
versus benefit discussion with the family.  This table and associated text indicate areas 
where consensus was reached.  Much discussion focused around the treatment of babies 
with less severe cCMV disease and whether the minimal additional benefit shown in the 6 
month treatment course was sufficient to justify such a prolonged course of treatment.  
Although clinical findings such as SGA and petechiae have been shown in historical cohorts 
to predict risk for SNHL, more recent re-analysis of data indicates that these findings in 
isolation are generally associated with disease-free outcomes in babies presenting without 
other manifestations of symptomatic disease.9;46  Opinion on the severity, or number, of 
symptoms justifying antiviral treatment remains divided and it is therefore strongly 
recommended that clinicians discuss treatment initiation and duration with an expert in this 
area.   
18 
 
Full consensus within this expert group was that:-  
1) Babies with evidence of CNS disease should receive antiviral treatment (Quality 
A, Strength 1).   Treatment should be preferably for 6 months duration (Quality 
B, Strength 2) 
2) Babies with no clinical/laboratory findings consistent with CMV disease should 
not receive treatment since no evidence exists to support treatment in this group 
(Quality D, Strength 1 (not to treat)). 
3) Babies with evidence of life-threatening disease or severe single organ disease 
and/or multi-organ involvement should receive treatment.  Although evidence is 
limited, particularly for life-threatening disease, consensus was that treatment 
should be considered in this group (Quality B, Strength 1).  Consensus could not 
be reached on duration of treatment in this group.  
4) Oral valganciclovir is now the drug of choice.  IV ganciclovir should be used in 
babies unable to tolerate oral drug or where gastrointestinal absorption is 
uncertain. (Quality A, Strength 1)  
The majority agreed that:- 
5) Babies with ‘mild’ cCMV disease (as defined earlier) should not receive 
treatment.  No studies have clearly addressed treatment in this group.  Most 
present at this meeting would not, therefore, treat babies with one or two 
isolated or transient, clinically insignificant, manifestations of disease. (Quality C, 
Strength 2) 
6) Babies with ‘moderate’ cCMV disease (as defined earlier).  Evidence for treating 
babies with multiple, but not severe, manifestations of disease (including 
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jaundice, hepatosplenomegaly without significantly raised liver enzymes, SGA) is 
limited.  It is therefore recommended that these cases are discussed on a case-
by-case basis with a clinician with experience of managing babies with cCMV 
(such as a pediatric infectious disease specialist)(Quality B, Strength 2).  
7) Treatment of isolated SNHL:   The majority at this meeting would include SNHL at 
birth in their indications for treatment since this was in the inclusion criteria for 
treatment in previous RCT’s.  Furthermore the main benefit of treatment is in 
preserving hearing rather than improving hearing once damage exists with good 
outcomes reported in observational studies (with likely bias).7;41;47  There was 
not, however, consensus and it is acknowledged that no RCT’s have specifically 
addressed treatment effect in this group of babies who are usually now 
identified through NHSPs (Grade C, Strength 1). 
8) Drug dose and formulation:  Although oral valganciclovir is now first line 
treatment in most cases it is currently unknown whether valganciclovir reaches 
target areas as effectively as ganciclovir or, indeed, where drug should be 
targeted (e.g. CNS or inner ear) since no studies have directly compared the two 
drugs.  In those with severe disease, particularly if absorption is uncertain, IV 
ganciclovir is therefore preferred by some in early stages of treatment until oral 
therapy can be reliably tolerated (Quality C, Strength 1).   
9) Treatment duration in cases without CNS involvement:  In those infants in whom 
the decision is taken to give antiviral treatment, the majority would treat for 6 
months.  However, there was not consensus on this point in light of the modest 




10) Treating babies older than 28 days: Treatment of older children has not been 
addressed in any RCTs although it is acknowledged that the 28 day cut-off is also 
not evidence-based.  Retrospective case series of small numbers of babies 
treated outside the newborn period have reported good outcomes.48;49   Babies 
found to have SNHL following hearing screening at birth often do not have a 
diagnosis of cCMV confirmed until outside the one month ‘window of evidence’ 
for treatment.  No consensus was reached on how late it might be acceptable to 
start treatment in this scenario, and/or in the eventuality of hearing 
deterioration.  Two RCT’s are currently evaluating the use of treatment in older 
children with cCMV and SNHL (clinicaltrials.gov NCT01649869 and NCT02606266) 
which may clarify this debate.   (Evidence for treating outside the newborn 
period Quality D, Strength 2) 
Side effects of antiviral treatment: 
Much of the debate around treating less severely affected babies relates to the potential 
side effects of currently available antiviral drugs. 
Significant neutropenia is frequently observed during antiviral treatment in infants.  This is 
reported less commonly with valganciclovir than with ganciclovir (21% compared to 
65%).7;41;44;50  Neutropenia generally occurs during the first month of treatment with no 
increased toxicity observed after 6 weeks in those randomized to receive 6 months 
treatment compared to placebo in the only RCT evaluating this.41  The oral administration of 
valganciclovir also removes the burden of hospitalization and risk of nosocomial infections 
and central line complications observed during treatment with ganciclovir.  Hepatotoxicity 
has been reported in up to 30% of those treated with ganciclovir and thrombocytopenia in a 
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similar proportion.51  In the most recent study of treatment with valganciclovir deranged 
liver function was observed but this was neither clinically nor statistically significant when 
compared to placebo.  In all studies abnormal biochemical and hematological parameters 
resolved following drug discontinuation.     
Long-term side effects have not been evaluated in neonates treated with ganciclovir or 
valganciclovir.  Animal studies raise the theoretical risk of gonadotoxicity and 
carcinogenicity.52;53  Although this has not been observed in humans to date parents should 
be counselled about these potential risks, particularly when considering treatment in those 
groups in which benefit has not been clearly shown.  No adverse long-term effects have 
been documented in a small cohort of babies treated in early neonatal studies and followed 
up to puberty (NCT00031421 – unpublished data). 
 
Monitoring of babies during treatment:  
Table 5 summarizes a proposed monitoring strategy for babies treated for cCMV.  These 
recommendations are based on the safety monitoring and data obtained from the published 
RCTs.7;41   
There are no data to support therapeutic drug monitoring (TDM).54  TDM may, however, 
have a role when toxicity is a concern (for example in those with impaired renal function) or 
where there are concerns about treatment response.   
Full consensus within this expert group was that:-  
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1) Where treatment is given babies should have regular weight measurement and 
safety monitoring to enable appropriate dose adjustment of medication (see 
Table 5).(Quality A, Strength 1)  
2) Where treatment is given parents should be fully counselled about both the 
known and potential side effects of treatment with current antivirals. (Quality A, 
Strength 1 for short-term side effects;  Long-term no published studies) 
3) Although there are theoretical risks of longer term treatment toxicity no large 
cohorts have been followed up to enable this to be fully evaluated in humans 
treated during early life.  Where possible children receiving antiviral treatment 
should therefore be entered into a registry to enable ongoing pharmacovigilance. 
Only a minority agreed that:- 
1) Viral load monitoring:  Some centers report monitoring viral load to assist in 
decisions regarding adequate drug dosing and detection of potential drug 
resistance; however, most experts at this meeting do not conduct this routinely.  
Treatment duration is not altered by any viral parameters and rebound of virus 
after treatment discontinuation is well-documented with no demonstrable 
association with long-term outcomes. (Quality D, Strength 2)  If viral load is 
checked after discontinuing drug it is suggested that parents are forewarned of 
the likelihood that virus will be detectable and that this is of unknown 




Table 5 summarizes recommended follow-up of babies with cCMV (both treated and 
untreated). 
The recommendation for audiological follow-up is based on long-term surveillance studies 
of SNHL in cCMV.4;16  Frequent follow-up is suggested during the first two years of life since 
this is the period of highest risk for development of cCMV-associated hearing loss and a 
critical period for language development.  Early detection of SNHL during this period is also 
most likely to improve long-term outcomes. 55  Monitoring should continue into early 
childhood, however, since deterioration in hearing continues throughout early life.55  
(Quality B, Strength 1) 
Neurodevelopmental follow-up is suggested at one and two years of age ideally with formal 
neurodevelopmental assessment.  This is not, however, routinely conducted in all centers 
and there is no evidence-based benefit in this particular group although early detection of 
functional impairments is generally agreed to be beneficial.   
Ophthalmic follow-up is recommended annually at least until children can talk in those with 
clinically detectable disease at birth, but not in those without, since deterioration in vision 
has been observed in this group. (Quality C, Strength 1).6   
Families should be given information for local/national support groups where these exist 
(see acknowledgements).  Where cCMV parent groups are not easily accessible parents of 
children with hearing loss may find support from groups for those with hearing impairment.  
Recommendations for future pediatric research 
1) Clinical trials addressing treatment of those with more ‘minor’ manifestations of 
disease/no clinically detectable disease at birth and those with isolated SNHL. 
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2) Clinical studies of antenatal therapies to decrease transmission of infection and 
cCMV disease once infection is established. 
3) Publications relating to cCMV should make it clear how those included were 
identified (i.e. babies presenting with clinically detected “symptoms” vs “screened” 
babies identified through existing antenatal or postnatal screening pathways 
including hearing screening programs), or following further investigation of 
abnormalities, such as thrombocytopenia, found incidentally when blood sampling is 
performed for other indications.   
4) Development of clinical prediction models to better categorize severity of disease 
(CNS vs non-CNS and babies with single vs multiple findings of disease) and 
associated outcomes to assist counselling of parents. 
5) Studies of neuroimaging, particularly MRI, and added-value with regards to 
predicting long-term impairments particularly in those without clinically detectable 
disease at birth through studies involving unselected cCMV cohorts.   
6) Clinical trials of alternative treatment durations and new anti-CMV therapies when 
available.  
7) Biomarkers.  It seems unlikely that a pre-defined duration of treatment will be 
similarly beneficial in babies with such varying clinical manifestations of disease and 
likely variable viral burden and host immune function.  The development of both 
host and virological biomarkers of long-term outcomes would greatly enhance 
design of future RCTs and enable more accurate counselling, and resource allocation. 
8) All children receiving treatment should be captured in a registry to enable ongoing 
pharmacovigilance for any long-term effects of antiviral medication. 
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9) Identification of risk factors for maternal virus transmission, particularly in those 
mothers with previous known exposure to CMV (CMV IgG seropositive).   
Conclusions 
As stated at the outset this article represents the consensus opinion of a group of 
professionals with a particular interest in cCMV.  It highlights that much of our practice is 
based on limited data, but identifies areas where there is nonetheless consensus amongst 
experts.  Recent publications have shown potential cost effectiveness of screening at birth 
for cCMV although these calculations are constrained by the issues raised in this article 
regarding true quantification of benefits of treatment and agreed treatment duration in 
certain patient groups.56;57   It will be challenging to address many of the research questions 
raised through RCT’s given the significant resources and long-term follow-up required 
alongside potential difficulties in recruiting into such studies when treatment is anecdotally 
being offered more freely.  Collecting accurate data on disease manifestations and 
treatment outcomes in different patient groups alongside maternal demographics can, 
however, inform treatment strategies as previously shown very effectively for the 
management of pediatric HIV.  This requires a unified approach to initial diagnostic tests, 
definitions of symptomatology and follow-up which is currently being addressed by a 
network of clinicians with an interest in this area through both national and European 
initiatives such as PENTA-ID, the ECCI and ESPID.  It should also be reiterated that this article 
focusses on postnatal aspects of diagnosis and treatment.  There is an associated and 
simultaneous need for work alongside obstetric and fetal medicine colleagues to address 
similar uncertainties in aspects of antenatal care.  It is hoped that through such 
26 
 
collaborations progress will be made in decreasing infection and disease in fetuses, 






The CMV-infected children and their parents/carers who we have cared for and who 2 
challenge us on a daily basis to provide evidence-based and consistent care including those 3 
parents who are involved with supporting other parents through local or national support 4 
groups including (but not exclusively):  CMV Action (www.cmvaction.org.uk); 5 
https://www.stopcitomegalovirus.org   6 
 7 
No grants were received in the production of this work. 8 
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Table 1: GRADE OF EVIDENCE (3) 
 
 
Quality rating  Definition Example methodology Depiction in text 
 
Strength of  
recommendation Definition     Depiction in text 
 
 
Strength of recommendations is determined by the balance between desirable and 
undesirable consequences of alternative management strategies, quality of evidence, 
variability in values and preferences, and resource use 
34 
 
Table 2: Possible signs and symptoms in children with congenital CMV 5-8 
CLINICALLY DETECTABLE SYMPTOMS/SIGNS 






Table 3:  Clinical features that should lead to testing for congenital CMV 
Neonates 
Older children 
Features in bold are those where there is consensus for testing 
Features in italics, are those that might lead to testing in individual circumstances and depending on local 
practice. 
 
1 Seek expert clinical virology advice for interpretation of virological investigations in pregnancy 
2 Baseline screening, to differentiate between congenital and postnatal CMV infection is helpful for extremely 
premature infants (<28 weeks gestational age), who are at increased risk of symptomatic postnatal infection. 
36 
 
Table 4: Summary of treatment recommendations 
Disease manifestation Treatment recommendation  Level of evidence 
37 
 
Table 5: Monitoring and follow up according to treatment status 
 
No treatment offered   Treatment offered 
 
 
